Fondazione Michelangelo at the San Antonio Breast Cancer Symposium

Fondazione Michelangelo at the San Antonio Breast Cancer Symposium Foundation’s experts and data in key educational sessions to share knowledge on the role of neoadjuvant therapy and imaging mass cytometry in breast cancer From the San Antonio Breast Cancer Symposium an important acknowledgement of the Michelangelo Foundation’s work and experts: Dr. Luca Gianni, co-founder of […]

Triple negative breast cancer, new therapeutic options and future strategies

Triple negative breast cancer, new therapeutic options and future strategies Lead by Michelangelo Foundation and Gianni Bonadonna Foundation’s experts, a review published on Nature Reviews – Clinical Oncology highlights the state of the art therapy in triple-negative breast cancer Triple-negative breast cancer has been viewed as the subtype with the least favorable outcomes for its […]

HER2+ and ER+ breast cancer, promising results with trastuzumab, pertuzumab and palbociclib

HER2+ and ER+ breast cancer, promising results with trastuzumab, pertuzumab and palbociclib NA-PHER2 trial, coordinated by Michelangelo Foundation, shows their efficacy as neoadjuvant therapy, with a relevant effect on Ki67 A neoadjuvant therapy with trastuzumab, pertuzumab and palbociclib reduces tumor proliferation, as shown by a drop in Ki67, in two expansion cohorts of the NA-PHER2 […]

Triple negative breast cancer, new data from Michelangelo Foundation’s NeoTRIP trial

Triple negative breast cancer, new data from Michelangelo Foundation’s NeoTRIP trial Atezolizumab added to nab-paclitaxel and carboplatin as neoadjuvant therapy did not increase the rate of pathological complete remission, mostly influenced by PD-L1 expression Triple negative breast cancer, new data from Michelangelo Foundation’s NeoTRIP trial Atezolizumab added to nab-paclitaxel and carboplatin as neoadjuvant therapy did […]

Breast cancer, a mechanism to bypass anti-ER and anti-HER2 resistance

Breast cancer, a mechanism to bypass anti-ER and anti-HER2 resistance CDK4/6 inhibition with palbociclib, in combination with fulvestrant, trastuzumab and pertuzumab, triggers sustained senescence: new data from a Michelangelo Foundation study Breast cancer, a mechanism to bypass anti-ER and anti-HER2 resistance CDK4/6 inhibition with palbociclib, in combination with fulvestrant, trastuzumab and pertuzumab, triggers sustained senescence: […]